Hostname: page-component-cd9895bd7-p9bg8 Total loading time: 0 Render date: 2024-12-23T23:57:34.867Z Has data issue: false hasContentIssue false
  • English
  • Français

Receptores IL-6 solubles en el suero y el líquido cefalorraquídeo de pacientes esquizofrénicos paranoides

Published online by Cambridge University Press:  12 May 2020

N. Müller ,
P. Dobmeier ,
M. Empl ,
M. Riedel ,
M. Schwarz  and
M. Ackenheil
N. Müller
Affiliation:
Hospital Psiquiátrico, Nussbamstrasse 7, D-80336, Munich, Alemania
P. Dobmeier
Affiliation:
Hospital Psiquiátrico, Nussbamstrasse 7, D-80336, Munich, Alemania
M. Empl
Affiliation:
Hospital Psiquiátrico, Nussbamstrasse 7, D-80336, Munich, Alemania
M. Riedel
Affiliation:
Hospital Psiquiátrico, Nussbamstrasse 7, D-80336, Munich, Alemania
M. Schwarz
Affiliation:
Hospital Psiquiátrico, Nussbamstrasse 7, D-80336, Munich, Alemania
M. Ackenheil
Affiliation:
Hospital Psiquiátrico, Nussbamstrasse 7, D-80336, Munich, Alemania
Get access

Resumen

Los niveles del receptor interleucina-6 soluble (sIL-6R) están íntimamente relacionados con los niveles de interleucina-6 (IL-6), y los sIL-6R aumentan las propiedades activadoras inmunes de la IL-6. Estimamos los niveles de sIL-6R en el suero en 25 pacientes esquizofrénicos y 25 controles sanos. En los pacientes, se midieron también los niveles de sIL-6R en el LCR. Las manifestaciones psicopatológicas se evaluaron según el sistema AMDP. Encontramos una correlación significativa entre los niveles del sIL-6R en el suero y en el LCR, lo que indica que los niveles en el suero pueden ser un marcador significativo para la acción central del sIL-6R. Además, se observaron correlaciones significativas entre el síndrome paranoide-alucinatorio y los niveles de sIL-6R tanto en el suero como en el LCR. Este resultado indica que la IL-6 desempeña un papel en los síntomas paranoides-alucinatorios en la esquizofrenia. Es posible entender esto en relación con la influencia de la IL-6 en la neurotransmisión catecolaminérgica. Los efectos reguladores por disminución del tratamiento neuroléptico sobre el sIL-6R demuestran que los niveles de sIL-6R disminuyen en el grupo entero de pacientes esquizofrénicos en comparación con los controles.

Keywords

citocinasinterleucina 6sIL-6Resquizofrenialíquido cefalorraquídeo
Type
Artículo original
Information
European Psychiatry (Ed. Española) , Volume 5 , Issue 4 , May 1998 , pp. 226 - 233
Copyright
Copyright © European Psychiatric Association 1998

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bibliografía

Arbeitsgemeinschaft für Methodik und Dokumentation in der Psychiatrie. Das AMDP System. Berlin: Springer, 1979.Google Scholar
Banks, WAKastin, AJGutiérrez, EG.Penetration of interleukin-6 across the murine blood-brain barrier. Neurosci Lett 1994; 179: 53-6.CrossRefGoogle ScholarPubMed
Bauer, KKornhuber, JBlood-cerebrospinal fluir barrier in schizophrenic patients. Eur Arch Psychiatr Neurol Sci 1987; 236: 257-9.CrossRefGoogle Scholar
Borbon, DBaumann, UAngst, JHelmchen, HHippius, H eds. AMDP System in Pharmacopsychiatry. Basel: Karger, 1983.Google Scholar
De Vries, HE Blom-Rosemalen MCM, van Oosten, Mde Boer, AGvan Berkel, TJC, Breimer, DDet al.The influence of cytokines to the integrity of the blood brain barrier in vitro. J Neuroimmunol 1996; 64: 37-43.CrossRefGoogle ScholarPubMed
Dunn, AJEndotoxin-induced activation of cerebral catecholamine and serotonin metabolism: comparison with interleukin-1. J Pharmacol Exp Ther 1992; 261: 96-49.Google ScholarPubMed
Frei, KMalipiero, UVLeist, TPZinkermagel, RMSchwab, MEFontana, AOn the cellular source and function of interleukin-6 produced in the central nervous system in viral diseases. Eur J lmmunol 1989; 19: 689-94.CrossRefGoogle ScholarPubMed
Galinowski, ABarbouche, RTruffinet, PLouzir, HPoirier, MFBouvet, Oet al.Natural autoantibodies in schizophrenia. Acta Psychiatr Scand 1992; 85: 240-2.CrossRefGoogle Scholar
Ganguli, RRabin, BSKelly, RH.Multiple autoantibodies and autoimmune disease in schizophrenic patients: evidence for an autoimmune pathogenesis. In: Hadden, JWMasek, KNistico, G eds. Interactions Among Central Nervous System, Neuroendocrine and Imniune Systems. Rome-Milan: Pythagora Press, 1989: 364-85.Google Scholar
Ganguli, RYang, ZShurin, GChengappa, RBrar, JSGubbi, AVet al.Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Res 1994; 51: 1-10.Google ScholarPubMed
Gebhardt, RPietzcker, AStrauss, AStoeckl, MLanger, CFreudenthal, KScale building in the AMDP System. Arch Psychiatr Neurol Sci 1983; 233: 223-45.Google Scholar
Groβkopf, AMüller, NMalo, AWank, R. HLA-DR and DQ alieles in schizophrenics and manic depressive disorders: potential role for the narcolepsy and multiple sclerosis associated allele DQB 1*0602 in schizophrenia subytpes. Schizophr Res 1996; (in press).Google Scholar
Hama, TKushima, YMiyamoto, MKubota, MTakei, NHatanaka, HInterleukin-6 improves the survival of mesencephalic catochelaminergic and septal cholinergic neurons from patnatal, two-week-old rats in cultures. Neuroscience 1991; 40: 445-52.CrossRefGoogle ScholarPubMed
Hornberg, MArolt, VWilke, IKruse, AKirchner, HProduction of interferons and lymphokines in leukocyte cultures of patients with schizophrenia. Schizophr Res 1995; 15: 237-42.CrossRefGoogle ScholarPubMed
Kirch, DGKaufman, CAPapadopoulos, NMMartin, BWeinberger, DRAbnormal cerebrospinal fluid protein indices in schizophrenia. Biol Psychiatry 1985; 20: 1039-46.CrossRefGoogle Scholar
Licinio, JSeibyl, JPAltemus, MCharney, DSKrystal, JHElevated levels of interleukin-2 in neuroleptic-free schizophrenics. Am J Psychiatry 1993; 150: 1408-10.Google Scholar
Mackiewicz, ASchooltink, HHeinrich, PCRose-John, S.Complex of soluble human IL-6-receptor/IL-6 upregulates expression of acute-phase proteins. J lmmunol 1992; 49: 2021-7.Google Scholar
Maes, MEvidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry 1995; 19: 11-38.CrossRefGoogle ScholarPubMed
Maes, MMeltzer, HYScharpe, SBosmans, ESuy, EDe Meester, Iet al.Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression. Psychiatric Res 1993a; 49: 11-27.Google ScholarPubMed
Maes, M Scharpé S, Meltzer, HYBosmans, ESuy, ECalabrese, Jet al.Relationships between lower plasma. L-Tryptophan levels and immune-inflammatory variables in depression. Psychiatry Res 1993b; 49: 151-65.CrossRefGoogle ScholarPubMed
Maes, MMeltzer, HYBosmans, EImmune-inflammatory markers in schizophrenics: comparison to normal Controls and effects of clozapine. Acta Psychiatr Scand 1994; 89: 346-51.CrossRefGoogle Scholar
Maes, MBosmans, EMeltzer, HY.Immunoendocrine aspects of major depression. Relationships between plasma interleukin-6 and soluble interleukin-2 receptor, prolactin and cortisol. Eur Arch Psychiatr Clin Neurosci 1995a; 245: 172-8.Google ScholarPubMed
Maes, MBosmans, ECalabrese, JSmith, RMeltzer, HY.Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res 1995b; 29: 141-52.Google ScholarPubMed
McAllister, CG van Kammen, DPRehn, TJMiller, ANGurklis, JKelley ME et al.Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am J Psychiatry 1995; 152: 1291-7.Google ScholarPubMed
Müller, N.The role of the cytokine-network in the CNS, and psychiatric disorders. Nervenarzt 1997; 68: 11-20.Google ScholarPubMed
Müller, NAckenheil, M.The immune system and schizophrenia: In: Leonard, BMiller, K eds. Stress, 1inmune System and Psychiatry. Chichester, New York: Wiley & Sons, 1995a: 137-64.Google Scholar
Müller, NAckenheil, M.Immunoglobulin and albumin contents of cerebrospinal fluid in schizophrenic patients: the relationship to negative symptomatology. Schizophr Res 1995b; 14: 223-8.Google ScholarPubMed
Müller, NAckenheil, MHofschuster, EMempel, WEckstein, RCellular immunity in shizophrenic patients before and during neuroleptic therapy. Psychiatry Res 1991; 37: 147-60.Google Scholar
Müller, NAkenheil, MHofschuster, EMempel, WEckstein, RInvestigation of the cellular immunity during depression and the free interval: evidence for an immune activation in affective psychosis. Prog Neuropsychopharmacol Biol Psychiatry 1993; 17: 713-30.CrossRefGoogle Scholar
üller, NEmpl, MPutz, ASchwarz, MAckenheil, MImmunological effects of treatment in schizophrenia. Adv Biol Psychiatry 1997; 18: 78-84.Google Scholar
Muraguchi, AHirano, TTang, BMatsuda, THorii, YNakajima, Ket al.The essential role of B-cell stimulating factor 2 (BSF-2/II6) for the terminal differentiation of the B-cells. J Exp Med 1988; 167; 332-44.CrossRefGoogle Scholar
Plata-Salaman, CR.Immunoregulators in the nervous System. Neurosci Behav Rev 1991; 15: 185-215.CrossRefGoogle ScholarPubMed
Saija, APrinci, PLanza, MScalese, MAramnejad, EDe Sarro, A.Systemic cytokine administration can affect blood-brain barrier permeability in the rat. Life Sci 1995; 56: 775-84.CrossRefGoogle ScholarPubMed
Sawada, MSuzumura, AMarunouchi, TTNF-a induces IL-6 production by astrocytes, but not by microglia. Brain Res 1992; 583: 296-9.CrossRefGoogle Scholar
Schöbitz, BPezeshki, GPohl, THermann, UHeinrich, PCHolsboer, Fet al.Soluble interleukin-6 (IL-6) receptor augments central effects of IL-6 in vivo. FASEB J 1995; 9: 659-64.Google Scholar
Seiler, WMüller, HHiemke, C.Diurnal variations of plasma interleukin-6 in man: methodological implications of continuous use of indwelling cannulae, An NY AcadSci 1995; 762: 468-70.CrossRefGoogle ScholarPubMed
Smith, RSA comprehensive macrophage-T-lymphocyte theory of schizophrenia. Med Hypotheses 1992; 39: 248-57.CrossRefGoogle ScholarPubMed
Song, CLeonard, BEAn acute phase protein response in the olfactory bulbectomised rat: effect of sertraline treatment. Med Sci Res 1994; 22: 313-4.Google Scholar
Zalcman, S Green-Johnson, JMMurray, LNance, DMDyck, DAnisman, Het al.Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6. Brain Res 1994; 643: 40-9.CrossRefGoogle ScholarPubMed